EAM
ALNY icon

Erste Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Erste Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
36,719
+409
+1% +$123K 0.08% 212
2026
Q1 		$11.5M Buy
36,310
+10,300
+40% +$3.51M 0.11% 180
2025
Q4 		$10.4M Hold
26,010
– – 0.09% 190
2025
Q3 		$11.6M Sell
26,010
-3,800
-13% -$1.55M 0.11% 173
2025
Q2 		$9.62M Buy
29,810
+6,500
+28% +$1.8M 0.08% 205
2025
Q1 		$6.26M Sell
23,310
-3,200
-12% -$822K 0.08% 204
2024
Q4 		$6.31M Buy
26,510
+10,000
+61% +$2.63M 0.08% 215
2024
Q3 		$4.54M Sell
16,510
-12,000
-42% -$3.12M 0.05% 250
2024
Q2 		$7.04M Hold
28,510
– – 0.09% 184
2024
Q1 		$4.4M Hold
28,510
– – 0.06% 241
2023
Q4 		$5.58M Hold
28,510
– – 0.08% 204
2023
Q3 		$4.96M Hold
28,510
– – 0.09% 204
2023
Q2 		$5.45M Hold
28,510
– – 0.1% 206
2023
Q1 		$5.56M Hold
28,510
– – 0.11% 195
2022
Q4 		$6.79M Sell
28,510
-2,420
-8% -$516K 0.14% 165
2022
Q3 		$6.48M Sell
30,930
-5,000
-14% -$954K 0.15% 172
2022
Q2 		$5.23M Hold
35,930
– – 0.12% 195
2022
Q1 		$5.94M Sell
35,930
-870
-2% -$133K 0.11% 196
2021
Q4 		$6.26M Hold
36,800
– – 0.11% 185
2021
Q3 		$6.53M Sell
36,800
-5,800
-14% -$1.09M 0.13% 175
2021
Q2 		$7.07M Hold
42,600
– – 0.14% 167
2021
Q1 		$5.76M Hold
42,600
– – 0.14% 168
2020
Q4 		$5.56M Sell
42,600
-13,000
-23% -$1.74M 0.15% 165
2020
Q3 		$8.06M Sell
55,600
-15,500
-22% -$2.2M 0.28% 106
2020
Q2 		$10.5M Hold
71,100
– – 0.42% 77
2020
Q1 		$7.74M Sell
71,100
-5,200
-7% -$600K 0.45% 64
2019
Q4 		$8.97M Buy
76,300
+1,400
+2% +$140K 0.4% 64
2019
Q3 		$6.07M Buy
74,900
+11,800
+19% +$934K 0.32% 85
2019
Q2 		$4.49M Hold
63,100
– – 0.24% 111
2019
Q1 		$5.72M Hold
63,100
– – 0.32% 83
2018
Q4 		$4.33M Buy
+63,100
New +$4.85M 0.29% 88

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Erste Asset Management's ALNY Position: Q2 2026 in Review

Erste Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 1.1% in Q2 2026, buying an estimated $123K and bringing the position to 36,719 shares worth $10.8M. The position accounts for 0.08% of the portfolio, ranked #212.

Erste Asset Management first reported a position in ALNY in Q4 2018 and has held it in 31 quarters since. The position peaked at $11.6M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Erste Asset Management held 36,719 shares of Alnylam Pharmaceuticals worth $10.8M as of Q2 2026.
  • Erste Asset Management bought 409 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $123K.
  • Alnylam Pharmaceuticals made up 0.08% of Erste Asset Management's portfolio in Q2 2026, its #212 holding.
  • Erste Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
  • Erste Asset Management's Alnylam Pharmaceuticals position peaked at $11.6M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.